Everolimus treatment of refractory epilepsy in tuberous sclerosis complex

Annals of Neurology

Volumn 74, Issue 5, 2013, Pages 679-687

  Krueger, Darcy A ^a   Wilfong, Angus A ^b   Holland Bouley, Katherine ^a   Anderson, Anne E ^b   Agricola, Karen ^a   Tudor, Cindy ^a   Mays, Maxwell ^a   Lopez, Christina M ^b   Kim, Mi Ok ^c   Franz, David Neal ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; FELBAMATE; LAMOTRIGINE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; ALLERGY; ANOREXIA; ARTICLE; BEHAVIOR; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; EPILEPSY; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROENTERITIS; GENOTYPE; HEMATOLOGIC DISEASE; HUMAN; KETOGENIC DIET; LUNG CONGESTION; MALE; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; OPEN STUDY; OTITIS MEDIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RASH; RHINORRHEA; SCHOOL CHILD; STOMATITIS; TABLET; TREATMENT DURATION; TUBEROUS SCLEROSIS; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT DISEASE;

EID: 84890806945     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23960     Document Type: Article

References (45)

1. O'Callaghan F, Shiell A, Osborne J, Martyn C,. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet 1998; 352: 318-319.
2. Krueger DA, Franz DN,. Current management of tuberous sclerosis complex. Pediatric Drugs 2008; 10: 299-313.
3. Curatolo P, Verdecchia M, Bombardieri R,. Tuberous sclerosis complex: a review of neurological aspects. Eur J Paediatr Neurol 2002; 6: 15-23.
4. Moavero R, Cerminara C, Curatolo P,. Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges. Childs Nerv Syst 2010; 26: 1495-1504.
5. de Vries P., Neurodevelopmental, psychiatric and cognitive aspects of tuberous sclerosis complex. In:, Kwiatkowsi DJ, Whittemore VH, Thiele EA, eds. Tuberous sclerosis complex. Weinheim, Germany: Wiley-Blackwell, 2010: 229-268.
6. Crino PB, Nathanson KL, Henske EP,. The tuberous sclerosis complex. N Engl J Med 2006; 355: 1345-1356.
7. Huang J, Manning B,. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008; 412: 179-190.
8. Bissler J, McCormack F, Young L, et al. Sirolimus for angiomyolipomata in tuberous sclerosis or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-151.
9. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 817-824.
10. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59: 490-498.
11. Krueger D, Care M, Holland-Bouley K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363: 1801-1811.
12. Franz D, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381: 125-132.
13. McCormack F, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364: 1595-1606.
14. Meikle L, Pollizzi K, Egnor A, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 2008; 28: 5422-5432.
15. Meikle L, Talos D, Onda H, et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci 2007; 27: 5546-5558.
16. Muncy J, IJ B, Koenig, M,. Rapamycin reduces seizure frequency in tuberous sclerosis complex. J Child Neurol 2009; 24: 477.
17. Zeng LH, Rensing NR, Wong M,. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 2009; 29: 6964-6972.
18. Zeng LH, Xu L, Gutmann DH, Wong M,. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008; 63: 444-453.
19. Roach ES, Gomez MR, Northrup H,. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998; 13: 624-628.
20. Aman M, Leone S, Lecavalier L, et al. The Nisonger Child Behavior Rating Form: typical IQ version. Int Clin Psychopharmacol 2008; 23: 232-242.
21. Aman MG, Tassé MJ, Rojahn J, Hammer D,. The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Res Dev Disabil 1996; 17: 41-57.
22. Sabaz M, Lawson JA, Cairns DR, et al. Validation of the Quality of Life in Childhood Epilepsy Questionnaire in American epilepsy patients. Epilepsy Behav 2003; 4: 680-691.
23. Napolioni V, Moavero R, Curatolo P,. Recent advances in neurobiology of tuberous sclerosis complex. Brain Dev 2009; 31: 104-113.
24. Wong M,. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies. Epilepsia 2010; 51: 27-36.
25. Zeng LH, Rensing NR, Wong M,. Developing antiepileptogenic drugs for acquired epilepsy: targeting the mammalian target of rapamycin (mTOR) pathway. Mol Cell Pharmacol 2009; 1: 124-129.
26. Tillema J, Leach J, Krueger D, Franz D,. Everolimus alters white matter diffusion in tuberous sclerosis complex. Neurology 2012; 78: 526-531.
27. Krueger D, Care M, Agricola K, et al. Everolimus long-term safety and efficacy in subependymal giant-cell astrocytoma. Neurology 2013; 80: 574-580.
28. Jõźwiak S, Kotulska K, Domańska-Pakieła D, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol 2011; 15: 424-431.
29. Prather P, de Vries P,. Behavioral and cognitive aspects of tuberous sclerosis complex. J Child Neurol 2004; 19: 666-674.
30. Agricola K, Tudor C, Krueger D, Franz D,. Nursing implications for the lifelong management of tuberous sclerosis complex. J Neurosci Nurs 2013; 45: 223-239.
31. Kotulska K, Chmielewski D, Borkowska J, et al. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol 2013; [Epub ahead of print doi: 10.1016/j.ejpn.2013.03.002 ].
32. Chan JA, Zhang H, Roberts PS, et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 2004; 63: 1236-1242.
33. Crino PB,. Malformations of cortical development: molecular pathogenesis and experimental strategies. Adv Exp Med Biol 2004; 548: 175-191.
34. Ehninger D, Han S, Shilyansky C, et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 2008; 14: 843-848.
35. Huang X, McMahon J, Huang Y,. Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy. Neuroscience 2012; 215: 90-97.
36. Parker WE, Orlova KA, Parker WH, et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med 2013; 5: 182ra53.
37. Huang X, Zhang H, Yang J, et al. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol Dis 2010; 40: 193-199.
38. Kwon C, Zhu X, Zhang J, Baker S,. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc Natl Acad Sci 2003; 100: 12923-12928.
39. Sunnen CN, Brewster AL, Lugo JN, et al. Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice. Epilepsia 2011; 52: 2065-2075.
40. Lee JH, Huynh M, Silhavy JL, et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet 2012; 44: 941-945.
41. Ljungberg MC, Bhattacharjee MB, Lu Y, et al. Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia. Ann Neurol 2006; 60: 420-429.
42. Ljungberg MC, Sunnen CN, Lugo JN, et al. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Dis Model Mech 2009; 2: 389-398.
43. Guo D, Zeng L, Brody DL, Wong M,. Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury. PLoS One 2013; 8: e64078.
44. Sha LZ, Xing XL, Zhang D, et al. Mapping the spatio-temporal pattern of the mammalian target of rapamycin (mTOR) activation in temporal lobe epilepsy. PLoS One 2012; 7: e39152.
45. Russo E, Citraro R, Donato G, et al. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. Neuropharmacology 2013; 69: 25-36.